Lunai Bioworks Inc. (LNAI) - Total Liabilities
Based on the latest financial reports, Lunai Bioworks Inc. (LNAI) has total liabilities worth $19.41 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check LNAI cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Lunai Bioworks Inc. - Total Liabilities Trend (2021–2025)
This chart illustrates how Lunai Bioworks Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Lunai Bioworks Inc. balance sheet assets.
Lunai Bioworks Inc. Competitors by Total Liabilities
The table below lists competitors of Lunai Bioworks Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kumulus Vape SA
PA:ALVAP
|
France | €11.06 Million |
|
Jackpot Digital Inc
V:JJ
|
Canada | CA$13.09 Million |
|
Nvni Group Limited Ordinary Shares
NASDAQ:NVNI
|
USA | $517.01 Million |
|
Buru Energy Ltd
AU:BRU
|
Australia | AU$14.49 Million |
|
Effnetplattformen Holding AB
ST:EFFH
|
Sweden | Skr2.65 Million |
|
Intensity Therapeutics, Inc. Common stock
NASDAQ:INTS
|
USA | $2.31 Million |
|
Hiap Huat Holdings Bhd
KLSE:0160
|
Malaysia | RM287.57 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Lunai Bioworks Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Lunai Bioworks Inc. (LNAI) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.97 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lunai Bioworks Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lunai Bioworks Inc. (2021–2025)
The table below shows the annual total liabilities of Lunai Bioworks Inc. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $29.58 Million | -5.04% |
| 2024-06-30 | $31.15 Million | +164.03% |
| 2023-06-30 | $11.80 Million | -1.79% |
| 2022-06-30 | $12.01 Million | -19.60% |
| 2021-06-30 | $14.94 Million | -- |
About Lunai Bioworks Inc.
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; a… Read more